Evidence map›Paper›PMID 40153243›Full record

ArticleObesity surgery2025

The Effect of Preoperative Single-Dose Tranexamic Acid on Bleeding and Thromboembolic Events Following Bariatric Surgery.

Nachum Emil Eliezer Lourie, Amram Kupietzky, Ata Maden, Shlomit Sharvit, Ariel Ronen, Melisa Umansky, Ido Mizrahi, Haggi Mazeh, Danny Ben-Zvi, Ronit Grinbaum

Abstract read
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nachum Emil Eliezer Lourie *Department of Surgery, Hadassah Medical center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Amram Kupietzky *Department of Surgery, Hadassah Medical center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. amramkupietzky@gmail.com.
Ata MadenDepartment of Surgery, Hadassah Medical center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Shlomit SharvitDepartment of Surgery, Hadassah Medical center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Ariel RonenDepartment of Anesthesiology, Hadassah Medical center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Melisa UmanskyDepartment of Anesthesiology, Hadassah Medical center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Ido MizrahiDepartment of Surgery, Hadassah Medical center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Haggi MazehDepartment of Surgery, Hadassah Medical center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Danny Ben-ZviDepartment of Developmental Biology and Cancer Research, The Institute for Medical Research Israel Canada, The Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Ronit GrinbaumDepartment of Surgery, Hadassah Medical center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntravenous tranexamic acid (TXA) has been shown to reduce perioperative blood loss and transfusion needs in various surgeries. However, its effectiveness in minimizing these complications during metabolic bariatric surgery remains unclear. This study aimed to determine whether a single prophylactic dose of intravenous TXA administered before metabolic bariatric surgery reduces the risk of perioperative hemorrhage.

methodsA retrospective analysis was conducted on patients who underwent metabolic bariatric surgery at our institute from 2019 to 2022, with routine TXA administration starting in 2021. A comparison was made between the TXA and non-TXA groups, with all surgeries performed by a single surgical team.

resultsA total of 901 patients were included, with 560 (62.2%) in the non-TXA group and 341 (37.8%) in the TXA group. There were no significant differences between groups in age, sex, or preoperative BMI, although a higher proportion of post-2021 patients underwent gastric bypass. No significant differences were observed in the percentage of patients with bloody surgical drains (4.2% vs. 4.9%, p = 0.662), transfusion need (1.5% vs. 1.6%, p = 1), re-operations for bleeding (3.2% vs. 2.3%, p = 0.582), or postoperative thromboembolic events (0.2% vs. 0%, p = 1.0).

conclusionsA single dose of intravenous TXA did not reduce postoperative bleeding in bariatric patients, nor were there significant differences in thromboembolic events or mortality between groups. Further randomized controlled trials are needed to confirm or refute TXA's effectiveness in reducing this potentially life-threatening complication.

Indexed as

Antifibrinolytic AgentsBariatric SurgeryBlood Loss, SurgicalPostoperative HemorrhageThromboembolismTranexamic AcidAdultFemaleHumansMaleMiddle AgedObesity, MorbidPreoperative CareRetrospective StudiesAntifibrinolytic AgentsTranexamic AcidBariatric surgeryGastric bypassLaparoscopyPostoperative hemorrhageSleeve gastrectomyTranexamic acid (TXA)

Identifiers

PMID40153243

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.